Hydroxide

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis2
46Malignant rheumatoid arthritis3
96Crohn disease1
IDDisease name (Link within this page)Number of trials
97Ulcerative colitis3
284Diamond-Blackfan anemia2

11. Myasthenia gravis


Clinical trials : 439Drugs : 223 - (DrugBank : 73) / Drug target genes : 50 - Drug target pathways : 135 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,543Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

96. Crohn disease


Clinical trials : 2,737Drugs : 1,197 - (DrugBank : 240) / Drug target genes : 182 - Drug target pathways : 221 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

97. Ulcerative colitis


Clinical trials : 3,305Drugs : 1,646 - (DrugBank : 318) / Drug target genes : 165 - Drug target pathways : 220 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

284. Diamond-Blackfan anemia


Clinical trials : 39Drugs : 95 - (DrugBank : 35) / Drug target genes : 34 - Drug target pathways : 131 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries